Stem Cell Clinic

Nine postdoctoral fellowships in aging research awarded by the Glenn Foundation for Medical Research and AFAR – EurekAlert

By Stell Cell Research

Announcing the 2022 Glenn Foundation for Medical Research Postdoctoral Fellowships in Aging Research Recipients

NEW YORK, NY and SANTA BARBARA, CA The American Federation for Aging Research (AFAR) and the Glenn Foundation for Medical Research are pleased to announce the recipients of the2022 Glenn Foundation for Medical Research Postdoctoral FellowshipsinAgingResearch.Thisprogramsupportspostdoctoralfellowswhostudybasicresearchmechanisms of aging and/or translational findings that have potential to directly benefit human health.

Selected through a rigorous review process,nine,one-year,$60,000Postdoctoral Fellowshipshavebeenawarded this year to advance research on a range of topics in the biology of aging, geroscience, and potential therapeutics:

"The fellowships significant research and training support to permit postdoctoral fellows to develop skills and competencies needed to become established in the field of aging, " notes Stephanie Lederman, EdM, Executive Director of AFAR. "With this recognition, and the ability to develop an independent research project, they are more competitive when vying for coveted junior faculty positions and when applying for larger grant support."

Theseawardsprovidepostdoctoralfellowstheopportunitytodevelopindependentresearchprojects, notes Mark R. Collins, President of the Glenn Foundation for Medical Research. Their findings today will help deepen knowledge, foster collaborations, and further therapeutic interventions tomorrow.

Learn more about this grant programhereand the 2022 recipientshere.

###

About the Glenn Foundation for Medical Research- Founded by Paul F. Glenn in 1965, the mission of the Glenn Foundation for MedicalResearchistoextendthehealthyyearsoflifethroughresearchonmechanismsofbiologythatgovernnormalhumanaging and its related physiological decline, with the objective of translating research into interventions that will extend healthspan with lifespan. Learn more atglennfoundation.org.

AboutAFAR-The American Federation for Aging Research (AFAR) is a national non-profit organization that supports and advances pioneering biomedical research that is revolutionizing how we live healthier and longer. For more than four decades, AFAR has served as the fields talent incubator, providing more than $193 million to nearly 4350 investigators at premier research institutions to dateand growing. In 2022, AFAR is expected to award over $11,000,000 to more than 60 investigators. A trusted leader and strategist, AFAR also works with public and private funders to steer high quality grant programs and interdisciplinary research networks. AFAR-funded researchers are finding that modifying basic cellular processes can delayor even preventmany chronic diseases, often at the same time. They are discovering that it is never too lateor too earlyto improve health. This groundbreaking science is paving the way for innovative new therapies that promise to improve and extend our quality of lifeat any age. Learn more atwww.afar.orgor follow AFARorg on Twitter and Facebook and American Federation for Aging Research on LinkedIn.

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.

Continue reading here:
Nine postdoctoral fellowships in aging research awarded by the Glenn Foundation for Medical Research and AFAR - EurekAlert

The Issue of Tissue: Getting to the Source of the HIV Reservoir – amfAR, The Foundation for AIDS Research

By Stell Cell Research

Not all stem cell transplants in individuals living with HIV and cancer, such as those used to cure Timothy Ray Brown and Adam Castillejo, among others, have been successful. Yet much can be learned about curing HIV from those whose lives could not be saved.

Research question Currently the only curative intervention for HIV is to transplant donor cells with a CCR5 delta32 genetic mutation in a person living with HIV (PLWH). But the impact of such transplants on HIV reservoirs in various organs has not been extensively characterized. A consortium of European researchers known as IciStem, established through amfAR funding, sought to gauge this impact by studying autopsy specimens from two individuals who underwent such transplants but were not cured and died soon afterwards.

Findings The first individual had been infected with HIV for 14 years and treated with antiretroviral therapy (ART) for that entire period. He was given a transplant in an attempt to cure a blood disorder known as MDS. On the 36th day following that procedure he achieved 100% chimerism. That meant that all his newly formed immune and other blood cells were the offspring of the donor and should be resistant to HIV infection. However, 29 days later that 100% value fell to 85%presumably related to an initially undetected population of recipient cells that were not destroyed by the transplant preparation procedure. He died of severe sepsis. At that time his blood still had no evidence of HIV, but all organs sampled, from brain to lymph node, showed signs of persistent infection.

The second individual had been infected with HIV for 22 years and treated with ART for the last 19 years. He required two transplants in an attempt to cure his acute leukemiathe first one having failed to take holdand on the 100th day following the first transplant (29 days after the second procedure) he achieved 100% chimerism. However, he died of lung failure eight days later. At that time no virus could be found in the blood, but the lymph node and spleen showed persistence of an HIV reservoir.

Impact The authors emphasize the need for examining tissues, not just blood, of PLWH having undergone potentially curative interventions as their results document that [t]issues play an essential role as a long-standing viral reservoir and routine [blood] sampling in living HIV-1-individuals will be insufficient to represent the extent of this reservoir.

amfARs role amfAR was a funder of this research.

Original article http://www.ncbi.nlm.nih.gov/pubmed/36146874

Dr. Laurence is amfARs senior scientific consultant.

See more here:
The Issue of Tissue: Getting to the Source of the HIV Reservoir - amfAR, The Foundation for AIDS Research

Platelet-Rich Plasma (PRP) Injections | Johns Hopkins Medicine

By Platelet Rich Plasma Injections

Featured Expert:

Platelet-rich plasma (PRP) injections are gaining popularity for a variety of conditions, from sports injuries to hair loss. The treatment uses a patients own blood cells to accelerate healing in a specific area.

Platelet-rich plasma consists of two elements: plasma, or the liquid portion of blood, and platelets, a type of blood cell that plays an important role in healing throughout the body. Platelets are well-known for their clotting abilities, but they also contain growth factors that can trigger cell reproduction and stimulate tissue regeneration or healing in the treated area. Platelet-rich plasma is simply blood that contains more platelets than normal.

To create platelet-rich plasma, clinicians take a blood sample from the patient and place it into a device called a centrifuge that rapidly spins the sample, separating out the other components of the blood from the platelets and concentrating them within the plasma.

After creating platelet-rich plasma from a patients blood sample, that solution is injected into the target area, such as an injured knee or a tendon. In some cases, the clinician may use ultrasound to guide the injection. The idea is to increase the concentration of specific bioproteins or hormones, called growth factors, in a specific area to accelerate the healing process.

The mechanism behind PRP injections is not completely understood. Studies show that the increased concentration of growth factors in platelet-rich plasma may stimulate or speed up the healing process, shortening healing time for injuries, decreasing pain and even encouraging hair growth.

PRP injections are used for a range of conditions,* from musculoskeletal pain and injuries to cosmetic procedures.

PRP injections may be able to treat a range of musculoskeletal injuries and conditions. For example, chronic tendon injuries such as tennis elbowor jumpers kneecan often take a long time to heal, so adding PRP shots to a treatment regimen can help to stimulate the healing process, decrease pain and enable a return to activities sooner.

Clinicians first used PRP to accelerate healing after jaw or plastic surgeries. Now, post-surgical PRP injections have expanded to help heal muscles, tendons and ligaments, as procedures on these tissues have notoriously long recovery times.

Early studies indicate that PRP injections may help treat osteoarthritis pain and stiffness by modulating the joint environment and reducing inflammation, but research is growing.

Our team of experts at the Johns Hopkins Musculoskeletal Center offers platelet-rich plasma injections to help alleviate pain, improve mobility and decrease inflammation.

PRP injections can be effective in treating male pattern baldness, both in preventing hair loss and promoting new hair growth. PRP can also aid in the stimulation of hair growth after hair transplants.

PRP injections are sometimes used as an anti-aging treatment, but there is little evidence to show that PRP reduces wrinkles and other signs of aging.

A PRP injection is a low-risk procedure and does not usually cause major side effects. The procedure involves a blood draw, so you should make sure you are hydrated and have eaten beforehand to prevent feeling lightheaded. After the procedure, you may experience some soreness and bruising at the injection site.

Because PRP injections are made up of your own cells and plasma, the risk of an allergic reaction is much lower than with other injectable medications like corticosteroids. Less common risks of PRP injections include:

If you are considering PRP injections, be sure to talk with your health care provider about all the benefits and risks.

*Research for the different applications of PRP is promising and rapidly growing. Although the equipment used to produce PRP and the injections themselves have been cleared by the FDA, this procedure is considered investigational and has not been officially approved by the FDA for most uses. Since PRP is a substance derived from ones own blood, it is not considered a drug. FDA clearance means that doctors can prescribe and administer PRP if they believe its in the best interest of the patient. However, lack of the FDA approval means that PRP treatments may not be covered by insurance.

Originally posted here:
Platelet-Rich Plasma (PRP) Injections | Johns Hopkins Medicine

Broncos Already Have A Week 6 Russell Wilson Update – Yardbarker

By Platelet Rich Plasma Injections

The Denver Broncos are among the more disappointing teams through Week 5 of the 2022 NFL season.

After hiring Nathaniel Hackett as head coach and trading for All-Pro quarterback Russell Wilson, there were high hopes for this team.

Football experts thought their additions would help the talented but underperforming Broncos offense.

Meanwhile, their fans were thrilled about Wilson completing touchdown passes to Jerry Jeudy, Courtland Sutton, and K.J. Hamler.

If that approach didnt work, the Broncos still had Javonte Williams and Melvin Gordon III from the backfield.

Unfortunately, the narrative did not unfold that way, as the Broncos have a losing record after five games.

They struggled to score or move the ball even before Williams suffered a season-ending injury.

However, Wilsons shoulder injury may explain his depressing start.

He has a torn lat in his throwing shoulder which is concerning for their prospects throughout the season.

But despite his condition, Wilson will still suit up for the Broncos in Week 6.

Read more:
Broncos Already Have A Week 6 Russell Wilson Update - Yardbarker

COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

By Global News Feed

LONDON, Oct. 04, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today the agenda for its virtual Capital Markets Day on 12 October 2022 at 8:00 am ET (1 pm UK).

Read the rest here:
COMPASS Pathways to Hold Virtual Capital Market Day on 12 October 2022

Castellum, Inc. Announces Intent to Uplist to NYSE American Exchange

By Global News Feed

POTOMAC, Md., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Castellum, Inc. (“Castellum”) (OTC: ONOV), a cybersecurity, electronic warfare, and IT services company, announced today that, subject to meeting all requirements (including the price requirement) at the time of listing, the Company’s application to list its shares of common stock (the “Common Stock”), has been approved to uplist to the NYSE American Exchange in conjunction with an underwritten public offering and a one-for-twenty reverse stock split of the Common Stock effective on or about October 7, 2022. The ticker symbol for the Common Stock will change to “CTM” upon listing. Trading of the Common Stock is expected to commence on or about October 7, 2022. The new CUSIP for the Common Stock following the reverse stock split will be 14838T204.

More:
Castellum, Inc. Announces Intent to Uplist to NYSE American Exchange

Correction: Dark Horse Consulting Group Welcomes Growth Investment from WestView Capital Partners

By Global News Feed

Walnut Creek, CA; Boston, MA, Oct. 04, 2022 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group ("DHC"), the leading global consultancy to the cell and gene therapy (“CGT”) industry, and WestView Capital Partners (“WestView”), a Boston-based growth equity firm, are pleased to jointly announce that WestView has completed a growth investment in DHC.

Here is the original post:
Correction: Dark Horse Consulting Group Welcomes Growth Investment from WestView Capital Partners

Psycheceutical Bioscience, Inc.’s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council

By Global News Feed

Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board Chief Visionary Officer of Psycheceutical, Zappy Zapolin, will join other prominent leaders in Psychedelics on Benzinga’s Council Board

Follow this link:
Psycheceutical Bioscience, Inc.'s Zappy Zapolin Added to The Benzinga Psychedelics Advisory Council

→←